Remepy is pioneering Hybrid Drugs: traditional drugs combined with digital therapeutics that are personalized and enhance the effect of pharmaceutical treatments. Remepy has already proven in human studies the effect of its products, using extensive brain imaging, as well as blood and saliva samples, with promising results for Oncology, MCI, and Parkinson's Disease. Their approach offers an efficient method to create new proprietary pharma assets, unlocking an entire new market and world of data. The Remepy team includes top scientists, physicians, and technologists.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/01/24 | $15,000,000 | Seed |
Firstime Venture Capital NFX  PsyMed Ventures Supernode Ventures Vine Ventures | undisclosed |
